Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (Mrna-4157) in Combination With Keytruda® (Pembrolizumab) After Neoadjuvant Keytruda and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (Nsclc)
默沙東和moderna啓動第3期試驗，評估V940（Mrna-4157）佐劑與Keytruda®（Pembrolizumab）在新輔助Keytruda和化療後對某些類型的非-小基站-5g肺癌（NSCLC）患者的療效
